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Abstract
Aims: To establish whether there is a difference in recovery of salivary function with bilateral superﬁcial lobe parotid-sparing intensity-modulated radiotherapy
(BSLPS-IMRT) versus contralateral parotid-sparing IMRT (CLPS-IMRT) in patients with locally advanced head and neck squamous cell cancers.
Materials and methods: A dosimetric analysis was carried out on data from two studies in which patients received BSLPS-IMRT (PARSPORT II) or CLPS-IMRT
(PARSPORT). Acute (National Cancer Institute, Common Terminology Criteria for adverse events e NCI CTCAEv3.0) and late (Late Effects of Normal Tissue-
subjective, objective, management analytical e LENTSOMA and Radiation Therapy Oncology Group) xerostomia scores were dichotomised: recovery (grade 0e1)
versus no recovery (grade 2). Incidence of recovery of salivary function was compared between the two techniques and dose-response relationships were
determined by ﬁtting dose-response curves to the data using non-linear logistic regression analysis.
Results: Seventy-one patients received BSLPS-IMRT and 35 received CLPS-IMRT. Patients received 65 Gy in 30 fractions to the primary site and involved nodal
levels and 54 Gy in 30 fractions to elective nodal levels. There were signiﬁcant differences in mean doses to contralateral parotid gland (29.4 Gy versus 24.9 Gy,
P < 0.005) and superﬁcial lobes (26.8 Gy versus 30.5 Gy, P ¼ 0.02) for BSLPS and CLPS-IMRT, respectively. Lower risk of long-term grade 2 subjective
xerostomia (LENTSOMA) was reported with BSLPS-IMRT (odds ratio 0.50; 95% conﬁdence interval 0.29e0.86; P ¼ 0.012). The percentage of patients who re-
ported recovery of parotid saliva ﬂow at 1 year was higher with BSLPS-IMRT compared with CLPS-IMRT techniques (67.1% versus 52.8%), but the difference was
not statistically signiﬁcant (P ¼ 0.12). For the whole parotid gland, the tolerance doses, D50, were 25.6 Gy (95% conﬁdence interval 20.6e30.5), k ¼ 2.7 (0.9e4.5)
(CLPS-IMRT) and 28.9 Gy (26.1e31.9), k ¼ 2.4 (1.4e3.4) (BSLPS-IMRT). For the superﬁcial lobe, D50 were similar: BSLPS-IMRT 23.5 Gy (19.3e27.6), k ¼ 1.9
(0.5e3.8); CLPS-IMRT 24.0 Gy (17.7e30.1), k ¼ 2.1 (0.1e4.1).
Conclusion: BSLPS-IMRT reduces the risk of developing high-grade subjective xerostomia compared with CLPS-IMRT. The D50 of the superﬁcial lobe may be a
more reliable predictor of recovery of parotid function than the whole gland mean dose.
 2016 The Royal College of Radiologists. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).
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Radiation-induced xerostomia is a common complica-
tion in the treatment of locally advanced head and neck
squamous cell cancers (LA-HNSCC) that can affect a pa-
tient’s quality of life [1,2]. Parotid-sparing intensity-Author for correspondence: C.M. Nutting, Head and Neck Unit, The Royal
Marsden NHS Foundation Trust, Fulham Road, London SW3 6JJ, UK.
E-mail address: chris.nutting@rmh.nhs.uk (C.M. Nutting).
http://dx.doi.org/10.1016/j.clon.2016.02.009
0936-6555/ 2016 The Royal College of Radiologists. Published by Elsevier Lt
creativecommons.org/licenses/by-nc-nd/4.0/).modulated radiotherapy (IMRT) techniques have shown a
reduced incidence of high-grade (grade 2) subjective
xerostomia at 1 year when compared with conventional
radiotherapy in two phase III randomised clinical trials
[3,4]. The PARSPORT trial spared the entire contralateral
parotid gland (mean dose 25.4 Gy) in the treatment of
oropharyngeal and hypopharyngeal cancers, whereas in the
nasopharyngeal cancer study an attempt was made to spare
both parotid glands (a mean dose of 32 Gy). Both studies
reported a 39% incidence of grade 2 subjective xerostomiad. This is an open access article under the CC BY-NC-ND license (http://
A.B. Miah et al. / Clinical Oncology 28 (2016) e69ee76e70described using the subjective component of LENTSOMA
and Radiation Therapy Oncology Group (RTOG), respec-
tively, in the IMRT arm.
The contralateral parapharyngeal space is often spared in
cases of LA-HNSCCwhere the disease at the primary site has
not crossed the midline and nodal disease is conﬁned to the
ipsilateral side. This allows contralateral parotid gland
sparing and elective irradiation of the contralateral lymph
nodes below the contralateral parapharyngeal space
(Figure 1a). However, many clinicians believe that bilateral
parapharyngeal space irradiation is essential in the treat-
ment of midline tumours of the head and neck, where
bilateral parapharyngeal space lymphatic drainage occurs
(base of tongue, soft palate, nasopharynx) and in patients
with bilateral nodal disease. In this situation, IMRT can be
used to deliver a bilateral superﬁcial lobe parotid-sparing
technique (BSLPS) (Figure 1b) [5].
The Quantitative Analysis of Normal Tissue Effects in the
Clinic (QUANTEC) committee recommended that additional
parotid toxicity studies should be undertaken to determine
if spatial/anatomic variations exist in local radiation effects
[6]. The aim of this study was to establish whether there is a
difference in the incidence of grade 2 subjective xero-
stomia and absence of parotid saliva ﬂow at 1 year with
BSLPS-IMRT versus contralateral parotid-sparing IMRT
(CLPS-IMRT) andwhether the dose-response relationship of
the parotid gland differs between the two techniques.Materials and Methods
Patients
Patients were treated in two prospective trials of parotid-
sparing IMRT. The ﬁrst was a phase III trial of conventionalFig 1. (a) Axial computed tomography image of contralateral parotid-spa
pharyngeal wall tumour. Colour wash: red-orange ¼ high dose (95e100% o
IMRT technique used also produces a dose gradient across the ipsilateral
superﬁcial lobe. (b) Axial computed tomography image of bilateral super
IMRT) for a midline tumour of the base of tongue. Colour wash: red-orang
of prescribed dose). The deep lobes of both parotid glands are included
pharyngeal spaces.radiotherapy versus CLPS-IMRT in the treatment of locally
advanced oropharyngeal and hypopharyngeal squamous
cell cancers (PARSPORT, ISRCTN48243537, CRUK/03/005)
[4]. The second was a phase II trial of BSLPS-IMRT technique
in the treatment of oropharyngeal and hypopharyngeal
cancers (PARSPORT II) [5]. The trials were approved by the
local committee of clinical research (CCR2059/MRECC03/6/
79 and CCR2588) and the research ethics committee. A
dosimetric analysis compared the IMRT-treated group of
the cohort of PARSPORT where CLPS-IMRT was used with
PARSPORT II where BLSPS-IMRT was delivered.
Treatment
In both studies, patients were immobilised and contrast-
enhanced computed tomography scans were acquired at
2e5 mm intervals through the primary tumour site and the
cervical lymph nodes. Gross tumour volumes, clinical target
volume for primary site and involved nodal groups (CTV1),
nodal groups at risk of harbouring microscopic disease
(CTV2), critical structures and parotid glands were delin-
eated according to trial protocol by the treating oncologists
[7]. The superﬁcial lobes of both parotid glands were out-
lined prospectively in the PARSPORT II patients and retro-
spectively in the PARSPORT IMRT patients by ABM.
Radiologically, the parotid gland was divided into the su-
perﬁcial and deep lobes by the retromandibular vein, as this
structure runs the same course as the facial nerve.
Radiotherapy was delivered using the ﬁve- or seven-
beam simultaneous integrated boost IMRT technique. A
dose of 65 Gy in 30 daily fractions was prescribed to the
median dose-volume point of the planning target volume
(PTV1) dose volume histogram (DVH), 54 Gy in 30 daily
fractions to PTV2 and the postoperative neck received 60 Gy
in 30 daily fractions. A dose constraint (mean dose ¼ 24 Gy)ring intensity-modulated radiotherapy (CLPS-IMRT) for a right lateral
f prescribed dose), blue ¼ low dose (20e30% of prescribed dose). The
parotid gland on the right, thus allowing modest sparing of the right
ﬁcial lobe parotid-sparing intensity-modulated radiotherapy (BSLPS-
e ¼ high dose (95e100% of prescribed dose), blue ¼ low dose (20e30%
in the high dose region because of their close proximity to the para-
A.B. Miah et al. / Clinical Oncology 28 (2016) e69ee76 e71was applied to the contralateral parotid gland in PARSPORT
IMRT patients. The superﬁcial lobes of both parotid glands
were combined as a single volume in PARSPORT II, with a
dose constraint (mean dose ¼ 24 Gy) applied for the plan-
ning and optimisation process. In addition, where possible,
a dose constraint (mean dose¼ 24 Gy) with a lower priority
was also applied to a whole contralateral parotid gland.
Chemotherapy
In PARSPORT, when indicated at the investigator’s
discretion, patients received induction chemotherapy,
comprising two 21-day cycles of cisplatin 75 mg/m2 on day
1 and 5-ﬂuorouracil 1000 mg/m2 on days 1e4. No
concomitant chemotherapy was delivered. In PARSPORT II,
patients aged 70 years or under with locally advanced dis-
ease received induction chemotherapy as above and
concomitant cisplatin (100mg/m2) or carboplatin (AUC¼ 5)
on days 1 and 29 of radiotherapy.
Data Collection
Mean doses to the ipsilateral and contralateral parotid
glands and the superﬁcial lobes were recorded. Acute
toxicity scores were recorded prospectively using NCI-
CTCAE v3.0 weekly during radiotherapy, weeks 1e4 and at
week 14 after radiotherapy [8]. Late toxicity scores (RTOG/
EORTC and LENTSOMA) were recorded at follow-up at 3, 6,
12 and 18 months after radiotherapy in both studies [9,10].
The methods used for parotid saliva collections have been
described previously [11,12]. Total parotid salivary ﬂow
rates were measured before radiotherapy and at 12 months
after radiotherapy applying the analytical component of
LENTSOMA scores. Where possible, measurements were
undertaken at similar times of the day for each patient.
Data Analysis and Statistical Methodology
The primary objective of this study was to determine the
difference in the incidence of grade 2 subjective xero-
stomia (LENTSOMA) between the two parotid-sparing IMRT
techniques at 1 year after IMRT. Secondary objectives
described the difference in the incidence of acute grade 2
subjective xerostomia during treatment, the incidence of
late grade 2 subjective xerostomia at 3, 6, 12 and 18
months after treatment and recovery of parotid saliva ﬂow
rates at 1 year after treatment. Descriptive statistics were
used to present the data. Statistical differences in pro-
portions were tested using chi-squared test or Fisher’s exact
test where appropriate. Student’s t-test was used to deter-
mine differences in continuous variables when normally
distributed and by Mann-Whitney if not. For serial depen-
dent datasets, Bonferroni’s method of multiple testing was
applied to determine statistical signiﬁcance and set at
P < 0.01. Generalised estimating equations using logistic
regression were used to account for differences in in-
cidences at and between speciﬁc time points. If recovery
was proven to be independent of these two factors, the odds
ratio was calculated to determine the risk of grade 2xerostomia between BSLPS-IMRT and CLPS-IMRT. A statis-
tical analysis was carried out using the Statistical Pro-
gramme for Social Sciences SPSSv18.0.
It was assumed that the organ of interest was organised
as a parallel structure. This provided the probability of a
deﬁned toxicity with an increasing mean dose to the organ
of interest. Mean doses were converted to equivalent dose
at 2 Gy per fraction (EQD2) using the Withers formula [13].
Dose-response curves were generated for grade 2 xero-
stomia at 1 year (combined superﬁcial lobes mean dose
with subjective xerostomia, whole parotid gland or super-
ﬁcial lobe with parotid saliva ﬂow). A logistic dose-response
curve with parameters D50 and k was ﬁtted using non-
linear logistic regression [14].
P ¼ 1
1þ ðD50=DÞk
where P is the probability of the incidence of toxicity; D is
the mean dose with D50, the mean dose at which 50% of
patients experience toxicity; k describes the increase in
incidence with increasing dose.Results
The PARSPORT trial recruited patients between
September 2002 and December 2007 from six UK centres.
Acute toxicity on all 47 patients and late toxicity with DVH
data on 35 patients who received IMRT in the PARSPORT
study were used for this analysis. The PARSPORT II study
recruited patients from a single centre between November
2005 and June 2010 [5]. Acute toxicity and DVH data were
available on 80 patients and late toxicity and DVH datawere
available for a subset of 71 patients who had at least 1 year
of follow-up. Patient characteristics are listed in Table 1 and
highlight the differences between the two groups in terms
of the use of induction and concomitant chemotherapy, the
proportion of patients who received postoperative radio-
therapy and the mean doses delivered to the parotid glands.
Human papillomavirus (HPV) status was positive in about
75% of the patients in PARSPORT II, but was unknown in the
PARSPORT study. Themean dose to the contralateral parotid
gland was signiﬁcantly lower in the CLPS-IMRT group
compared with the BSLPS-IMRT group (24.9 Gy versus 29.4
Gy; P < 0.005). The mean dose to the ipsilateral parotid
glandwas signiﬁcantly lower in the BSLPS-IMRTgroup (38.9
Gy versus 45.7 Gy; P < 0.005). As expected, with BSLPS-
IMRT as used in the PARSPORT II trial, the mean dose to
the superﬁcial lobes was signiﬁcantly lower in this group
when compared with the CLPS-IMRT (PARSPORT) trial (26.8
Gy versus 30.5 Gy; P ¼ 0.02).
Prevalence and Incidence of Xerostomia
Acute xerostomia
The prevalence of grade 2 dry mouth symptoms was
similar in weeks 1e6 in both groups. The peak prevalence
was at the end of treatment at week 6 for BSLPS-IMRT pa-
tients (59%) and was 70% in the CLPS-IMRT patients at week
Table 1
Patient characteristics andmean doses to parotid glands: PARSPORT (contralateral parotid-sparing intensity-modulated radiotherapy; CLPS-
IMRT) and PARSPORT II (bilateral superﬁcial lobe parotid-sparing intensity-modulated radiotherapy; BSLPS-IMRT)
Patient characteristics PARSPORT IMRT
(CLPS) (n ¼ 35)
PARSPORT II
(BSLPS) (n ¼ 71)
Median age (years) 59.9 56.5
Male gender (%) 25 (71) 56 (79)
Primary site (%)
Oropharynx 28 (80) 66 (93)
Hypopharynx 7 (20) 5 (7)
AJCC TNM stage (%)
IeII 13 (36) 3 (4)
III 11 (33) 13 (19)
IVA 10 (28) 55 (77)
IVB 1 (3) 0 (0)
Induction chemotherapy (%) 13 (37) 54 (76)
Primary radiotherapy (%) 26 (74) 60 (84)
Postoperative radiotherapy (%) 9 (26) 11 (16)
Concomitant chemotherapy (%) 0 (0) 57 (80)
Contralateral parotid gland mean dose (Gy) ( 1 standard deviation) 24.9 (14.7e32.2) 29.4 (22.8e36.0)
P value CLPS versus BSLPS <0.005
Ipsilateral parotid gland mean dose (Gy) ( 1 standard deviation) 45.7 (21.5e60.6) 38.9 (34.3e43.5)
P value CLPS versus BSLPS <0.005
Combined superﬁcial lobes of parotid glands mean dose (Gy) ( 1 standard deviation) 30.5 (23.1e37.9) 26.8 (23.0e30.6)
P value CLPS versus BSLPS ¼0.02
A.B. Miah et al. / Clinical Oncology 28 (2016) e69ee76e727. Resolution of grade 2 dry mouth symptoms occurred
earlier in the BSLPS-IMRT group with a signiﬁcant differ-
ence in prevalence rates at week 8, 2 weeks after
completing radiotherapy (CLPS-IMRT 63.8% versus BSLPS-
IMRT 46.7%, P ¼ 0.008) (Figure 2).
Late Subjective Xerostomia
BSLPS-IMRT patients reported a statistically signiﬁcant
reduction in incidence of high-grade xerostomia (LENT-
SOMA) at 3 and 6 months, but this was not signiﬁcant at 12
and 18 months compared with CLPS-IMRT (Figure 3a).0
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Fig 2. The prevalence of acute high-grade dry mouth changes at each
time point during and after contralateral parotid-sparing intensity-
modulated radiotherapy (CLPS-IMRT) and bilateral superﬁcial lobe
parotid-sparing intensity-modulated radiotherapy (BSLPS-IMRT).Using the RTOG scoring scales, a statistically signiﬁcant
improvement in xerostomiawas observedwith BSLPS-IMRT
at 12 months, but was borderline at 6 months, and was not
signiﬁcant at 18 months (Figure 3b). Generalised estimating
equations showed that there was no interaction between
the time from IMRT completion and IMRT technique used.
Evaluating the risk of developing high-grade xerostomia,
the odds ratio showed a lower risk of developing high-grade
xerostomia with BLSLPS-IMRT when compared with CLPS-
IMRT (LENTSOMA odds ratio 0.50, 95% conﬁdence interval
0.29e0.86, P ¼ 0.012; RTOG odds ratio 0.49, 95% conﬁdence
interval 0.28e0.86, P ¼ 0.014).
Analytical Measure of Late Xerostomia
Parotid saliva ﬂow rates at 1 year were reported on 35
patients in the PARSPORT IMRT cohort and 35 patients in
the PARSPORT II study. Apart from absence of parotid saliva
production, technical difﬁculties and/or patient discomfort
were the most common reasons for no saliva collection. The
incidence of recovery of parotid salivary ﬂow at 1 year after
radiotherapy was 67.1% with BSLPS-IMRT versus 52.8% with
CLPS-IMRT (P ¼ 0.12).
Dosimetric Analyses and Calculation of Parotid Gland
Tolerance
Dose-response parameters, D50 and k for grade 2
subjective xerostomia are summarised in Table 2. D50 and k
for CLPS-IMRT with LENTSOMA analysis (D50 ¼ 34.6 Gy,
k ¼ 4.6) were similar to BSLPS-IMRT (D50 ¼ 32.6 Gy,
k ¼ 3.3). The differences between the two scoring systems
for both CLPS- and BLSLPS-IMRT were evident, with higher
D50 values for RTOG scores.
Fig 3. The incidence of high-grade subjective xerostomia with (a) LENTSOMA and (b) Radiation Therapy Oncology Group (RTOG) scoring system
for the contralateral parotid-sparing intensity-modulated radiotherapy (CLPS-IMRT) and bilateral superﬁcial lobe parotid-sparing intensity-
modulated radiotherapy (BSLPS-IMRT) (chi-squared test for proportions, P < 0.05 statistically signiﬁcant).
A.B. Miah et al. / Clinical Oncology 28 (2016) e69ee76 e73The dose-response curves indicating the probability of
no recovery of parotid salivary ﬂow at 1 year are presented
in Figure 4. The two parotid-sparing techniques are shown
together for (a) whole parotid and (b) superﬁcial lobe.
Corresponding parameter values are detailed in Table 3.
Figure 4a illustrates a slightly higher D50 value for the
BSLPS-IMRT group when compared with the CLPS-IMRT
group (28.9 Gy versus 25.6 Gy) but with similar gradients
(k) (2.7 versus 2.4). The two dose-response curves for the
superﬁcial lobe alone (Figure 4b) are in good agreement.Discussion
This study has shown that the prevalence of high-grade
acute and late subjective xerostomia is signiﬁcantly lower
in patients who received radiotherapy using the BSLPS-
IMRT technique, with the overall risk of developing high-
grade xerostomia with time lower with BSLPS-IMRT
compared with CLPS-IMRT. The PARSPORT trial [4] deliv-
ered CLPS-IMRT, whereas the PARSPORT II trial [5] deliveredTable 2
Summary of D50 and k values and EQD2 values with 95% conﬁdence int
subjective scoring systems
Sub
LEN
Combined superﬁcial lobes
CLPS
D50 (Gy; 95% conﬁdence interval) 34.6
EQD2 D50 (Gy; 95% conﬁdence interval) 35.8
k 4.6
BSLPS
D50 (Gy; 95% conﬁdence interval) 32.6
EQD2 D50 (Gy; 95% conﬁdence interval) 33.7
k 3.3
CLPS, contralateral parotid sparing; BSLPS, bilateral superﬁcial lobe par
LENTSOMA, Late Effects of Normal Tissue- subjective, objective, manag
RTOG, Radiation Therapy Oncology Group.BSLPS-IMRT. Both studies described the same primary end
point: incidence ofgrade 2 subjective xerostomia at 1 year
and measured recovery at identical time points, thus
providing an unique opportunity to compare outcomes
between the two techniques. Although CLPS-IMRT has been
proven in a phase III study to reduce the incidence of
xerostomia without compromising on locoregional control,
the technique cannot be applied to treatment of tumours in
which both parapharyngeal spaces are at risk of harbouring
microscopic disease. The requirement to irradiate the
bilateral parapharyngeal spaces in head and neck cancer
patients is controversial. This is reﬂected in variations in
clinical practice and also in trial quality assurance guide-
lines in the UK and internationally. It is up to clinicians to
weigh up the risk of involvement of the parapharyngeal
space by microscopic tumour metastases for individual
patients and to decidewhether or not to include this in their
CTV. The BSLPS-IMRT technique was designed to test the
hypothesis that effective radiotherapy can be delivered to
the bilateral parapharyngeal spaces and still avoid xero-
stomia. BSLPS-IMRT may still increase the risk of localerval for developing high-grade subjective xerostomia as scored by
jective xerostomia
TSOMA
Subjective xerostomia
RTOG
(30.6e38.8) 36.1 (27.0e45.1)
(31.6e40.1) 37.3 (27.9e46.6)
(1.5e7.6) 2.9 (e0.2e6.2)
(24.3e41.1) 39.0 (29.5e48.5)
(25.1e42.5) 40.3 (30.5e50.1)
(0.4e7.6) 3.2 (0.9e5.5)
otid sparing.
ement analytical.
Fig 4. Dose-response curves of (a) whole parotid gland and (b) superﬁcial lobe describing the probability of no recovery of parotid saliva ﬂow at
1 year generated using non-linear logistic regression analysis, error bars representing 1 standard error of mean. The parameters are summarised
in Table 2.
A.B. Miah et al. / Clinical Oncology 28 (2016) e69ee76e74relapse in the superﬁcial parotid gland in patients whose
tumour lymphatic drainage is directed to the pre-auricular
nodes, such as cutaneous squamous cell carcinoma or
very advanced nasopharyngeal carcinoma. The superior
outcomes observed with BSLPS-IMRT suggest that addi-
tional sparing of the ipsilateral superﬁcial lobe with CLPS-
IMRT may further reduce grade 2 xerostomia. These out-
comes offer additional evidence to the QUANTEC committee
to recommend dose volume limits to reduce xerostomia
risk. This study has also addressed one of the questions
posed by QUANTEC, namely to determine the spatial/
anatomic variation of radiation effect [6].
The effect of concomitant chemotherapy on parotid
function is uncertain. Eighty per cent of patients received
concomitant chemotherapy in the BSLPS-IMRT group. Hey
et al. [15] reported a lower tolerance dose (TD50) with
chemoradiotherapy versus radiotherapy alone when
measuring high-grade xerostomia at 6 months. However,
multivariate analyses by Eisbruch et al. [16] and Chao et al.
[17] reported that chemotherapy did not have a deleterious
effect on parotid function. Data from our group haveTable 3
D50 and k parameters (EQD2) with 95% conﬁdence interval for probab
W
CLPS
D50 (Gy; 95% conﬁdence interval) 2
EQD2 D50 (Gy; 95% conﬁdence interval) 2
k 2
BSLPS
D50 (Gy; 95% conﬁdence interval) 2
EQD2 D50 (Gy; 95% conﬁdence interval) 3
k 2
CLPS, contralateral parotid sparing; BSLPS, bilateral superﬁcial lobe parsuggested that concurrent chemotherapy did not increase
the tolerance dose of the parotid gland to radiotherapy [18].
This was conﬁrmed in this study: the incidence of
acute grade 2 subjective xerostomia was lower in the
BSLPS-IMRT group compared with the CLPS-IMRT group
and late grade 2 subjective xerostomia at 1 year was
similar to CLPS-IMRT.
The incidence of acute grade 2 dry mouth symptoms
during IMRT was similar in both studies. The peak prev-
alence was higher and later (1 week after IMRT) with
CLPS-IMRT. Recovery seemed to be slower with CLPS-
IMRT, with a signiﬁcant difference between the two
groups at week 8 (2 weeks after IMRT). Despite the
contralateral parotid gland mean dose being signiﬁcantly
lower with CLPS-IMRT when compared with BSLPS-IMRT
(24.9 Gy versus 29.4 Gy, P < 0.005), the incidence of
grade 2 subjective xerostomia at 1 year was similar in
both groups. Although there was some difference between
analyses using LENTSOMA versus RTOG, presumably due
to the differences in deﬁnition of grade 2 xerostomia in
these measures, BSLPS-IMRT consistently produced aility of no recovery of parotid saliva ﬂow at 1 year
hole parotid gland Superﬁcial lobe
5.6 (20.6e30.5) 24.0 (17.7e30.1)
6.6 (21.5e31.7) 24.8 (18.3e31.1)
.7 (0.9e4.5) 2.1 (0.7e4.1)
8.9 (26.1e31.9) 23.5 (19.3e27.6)
0.0 (27.0e32.9) 24.3 (20.0e28.5)
.4 (1.4e3.4) 1.9 (0.5e3.8)
otid sparing.
A.B. Miah et al. / Clinical Oncology 28 (2016) e69ee76 e75lower incidence of high-grade xerostomia compared with
CLPS-IMRT. This can partly be explained by the mean
doses delivered to the ipsilateral parotid gland and su-
perﬁcial lobes. Lower mean doses were delivered to these
structures with BSLPS-IMRT, which reduced the proba-
bility of damage to the ipsilateral parotid gland. Other
studies that have delivered BSLPS-IMRT have reported a
similar incidence of high-grade xerostomia at 1 year. Kam
et al. [3] reported an incidence of high-grade subjective
xerostomia (RTOG scores) of 39% at 1 year in patients
treated for nasopharyngeal cancers with a mean dose to
the parotid glands of 32 Gy, whereas the University of
California-San Francisco reported 28% high-grade xero-
stomia (RTOG scores) at 1 year with 34 Gy to 50% and 24.6
Gy to 80% of each parotid gland [19].
BSLPS-IMRT yielded a higher incidence of recovery of
parotid saliva ﬂow than CLPS-IMRT (67.1% versus 52.8%),
but this did not achieve statistical signiﬁcance (P ¼ 0.12).
Chao et al. [17] reported dose-response relationships of the
parotid gland in patients who underwent BSLPS-IMRT for
the treatment of LA-HNSCC. The mathematical model used
implied if both parotid glands received a mean dose of
greater than 32 Gy then this predicted a high probability of
grade 4 xerostomia (measured by the analytical compo-
nent of LENTSOMA). However, in that study whole mouth
saliva ﬂow rates were used to measure xerostomia without
accounting for contributions from other salivary glands.
Also, the primary end point was measured at 6 months e a
time point that is too early to determine optimal recovery.
Pow et al. [1] reported recovery of parotid saliva ﬂow rate
at 1 year in 83% of patients despite mean parotid gland
doses of 42 Gy and 41 Gy. At these mean doses, it was
anticipated that there would be no recovery of salivary
ﬂow; this provides further evidence that the mean dose to
the superﬁcial lobes may play a more inﬂuential role in the
recovery of parotid saliva ﬂow. Similar conclusions were
made by others for advanced nasopharyngeal carcinoma
[20,21].
The D50 of the parotid gland after delivering BSLPS-IMRT
was reported as 28.9 Gy and in those who received CLPS-
IMRT was 25.6 Gy. The discrepancy between the two can
be explained by the volume of parotid tissue spared with
each technique. BSLPS-IMRT attempted partial sparing of
both parotid glands, which allowed a higher dose to each
gland to achieve the same effect. By contrast, CLPS-IMRT
assumed that the ipsilateral parotid gland was irradiated
to a dose above tolerance with no recovery anticipated.
Therefore, the contralateral parotid gland required a lower
tolerance dose to spare as much of the parotid tissue to
achieve the same effect. Further analysis to determine the
D50 values of the superﬁcial lobe reported similar doses
using either IMRT technique, suggesting that the mean dose
to this part of the parotid gland may be a more reliable
predictor of recovery of function. However, as our group has
concluded previously, subjective reports of xerostomia are
probably the most representative measure of patient
beneﬁt [22]. Based on the results of other studies, further
reductions in xerostomia can be expected up to 2 years after
treatment.Preclinical studies of rat parotid glands have described
the glands to have regional differences in radiosensitivity.
Konings et al. [21] reported that a single dose of 30 Gy to the
entire parotid gland resulted in complete loss of parotid
ﬂow, whereas there was a 65% reduction in saliva ﬂow
when only the cranial part of the gland was irradiated to 30
Gy and a 25% reduction in saliva ﬂow when only the caudal
part was irradiated to 30 Gy. Irradiation of the cranial part of
the gland involved shielding of the lateral lobe. Irradiation
of 50% of the cranial volume led to secondary damage to the
lateral lobe. The inverse did not occur. Pringle et al. [23]
described that the salivary gland stem/progenitor cells
resided in the main excretory ducts, of which a large pro-
portion populate the cranial part of the gland. This may
explainwhy radiation to the cranial component may lead to
extensive secondary damage of the caudal part of the gland.
An analogy between the rat parotid gland and the human
parotid gland could bemade. The superﬁcial lobe consists of
a larger volume of parotid tissue and importantly it is where
the main secretory (Stensen’s) duct resides. If, like the rat
parotid gland, the progenitor cells are in themain duct, then
sparing of both superﬁcial lobes, and the parotid gland stem
cells within the main ducts, may lead to less stem cell
damage and quicker recovery of salivation in humans [23].
This is supported by the low D50 (23.5 Gy) value of the
superﬁcial lobe and suggests that the superﬁcial lobe may,
in fact, be more radiosensitive and provide evidence that
not only volume effects, but also regional variations in
radiosensitivity, can affect recovery of salivary function.
The limitations of this study were that this was a non-
randomised comparison with relatively small numbers of
patients with different tumour stages and subsites and that
different chemotherapy schedules were used. The propor-
tion of HPV-positive patients in these in PARSPORT II is
known and stated but unknown in PARSPORT; however, we
think this probably did not have an effect on the results.
Neither of the two techniques used in this comparative
study attempted to spare the submandibular salivary glands
as the level 1B lymph nodes were included in the CTV.
Sparing of these smaller salivary glands may further reduce
xerostomia, but may increase the risk of nodal relapse of
cancer in level 1B.
In summary, this study has described that BSLPS-IMRT
led to reductions in the incidence of high-grade xero-
stomia comparedwith CLPS-IMRT. This technique should be
considered in appropriate patients.
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